1-(1-phenylpropyl)pyrrolidine | 92195-57-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(1-phenylpropyl)pyrrolidine
• 英文别名: 1-(1-phenyl-propyl)-pyrrolidine；1-phenylpropylpyrrolidine；phenylpropylpyrrolidine；1-Pyrrolidino-1-phenyl-propan
• CAS: 92195-57-8
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: CNCVMCNGUPWUSW-UHFFFAOYSA-N

物化性质

• 沸点：
  95-115 °C(Press: 15 Torr)
• 密度：
  0.986±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  三乙基铝 、 1-benzylidenepyrrolidinium triflate 以 正己烷 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 1-(1-phenylpropyl)pyrrolidine
  参考文献：
  名称：

  有机铝试剂，甲硅烷基化胺和醛的铝-曼尼希反应

  摘要：

  使用有机铝试剂，甲硅烷基化胺和醛进行多组分偶联会形成叔胺。烯基和烷基铝试剂均与亚胺离子底物发生反应，而相应的Petasis borono-Mannich反应不成功。

  DOI：

  10.1002/chem.201801012

文献信息

• [EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS BENZÈNESULFONAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2017201468A1

  公开（公告）日：2017-11-23

  This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

  本发明涉及苯磺酰胺化合物，包括它们的立体异构体、对映异构体、互变异构体或其混合物；或用于治疗与电压门控钠通道相关的疾病或病症的药用可接受盐、溶剂化物或前药，例如癫痫。
• [EN] METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ DÉRIVÉ D'ALIZARINE, NOUVEAU COMPOSÉ DÉRIVÉ D'ALIZARINE, PROCÉDÉ DE MODIFICATION DE SURFACE, FILM DE CONVERSION PHOTOÉLECTRIQUE, ÉLÉMENT DE CONVERSION PHOTOÉLECTRIQUE ET PHOTORÉCEPTEUR ÉLECTROPHOTOGRAPHIQUE
  申请人：FUJIFILM CORP

  公开号：WO2011071130A1

  公开（公告）日：2011-06-16

  The present invention provides a novel alizarin derivative compound and a simplified and low cost method for preparing an alizarin derivative compound including: obtaining a compound represented by Formula (2) using a compound represented by Formula (3); and obtaining an alizarin derivative compound represented by Formula (1) using the compound represented by Formula (2); in Formulae (1) to (3), R1 represents a hydrogen atom or a substituent; n represents an integer of 1 to 3, L represents a specific alkyl group; Q represents an atomic group needed to form an aromatic ring or a heteroaromatic ring with adjacent carbon atoms; and P represents an atomic group which includes an atom(s) selected from a hydrogen atom, a carbon atom, an oxygen atom, a sulfur atom, a silicon atom and a boron atom, and which is needed to form a ring structure group with adjacent two oxygen atoms and two carbon atoms; Formula (1) Formula (2) Formula (3).

  本发明提供了一种新型茜素衍生物化合物以及一种简化且低成本的制备茜素衍生物化合物的方法，包括：使用表示为Formula (3)的化合物获得表示为Formula (2)的化合物；并使用表示为Formula (2)的化合物获得表示为Formula (1)的茜素衍生物化合物；在Formulae (1)到(3)中，R1代表氢原子或取代基；n代表1至3的整数，L代表特定的烷基团；Q代表需要与相邻碳原子形成芳香环或杂芳环的原子团；P代表包括从氢原子、碳原子、氧原子、硫原子、硅原子和硼原子中选择的原子的原子团，并且需要与相邻的两个氧原子和两个碳原子形成环结构团；Formula (1) Formula (2) Formula (3)。
• [EN] PYRIDINE AMIDE DERIVATIVES<br/>[FR] DÉRIVÉS PYRIMIDINAMIDES
  申请人：NOVARTIS AG

  公开号：WO2013038373A1

  公开（公告）日：2013-03-21

  The present invention provides pyridine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供吡啶衍生物，可恢复或增强突变和/或野生型CFTR的功能，用于治疗囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、干燥综合征和角膜结膜炎，或便秘（肠易激综合征、炎症性肠病、阿片类药物诱导）。还包括含有这些衍生物的药物组合物。
• METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR
  申请人：Takahashi Keita

  公开号：US20120244462A1

  公开（公告）日：2012-09-27

  The present invention provides a novel alizarin derivative compound and a simplified and low cost method for preparing an alizarin derivative compound including: obtaining a compound represented by Formula (2) using a compound represented by Formula (3); and obtaining an alizarin derivative compound represented by Formula (1) using the compound represented by Formula (2); in Formulae (1) to (3), R 1 represents a hydrogen atom or a substituent; n represents an integer of 1 to 3, L represents a specific alkyl group; Q represents an atomic group needed to form an aromatic ring or a heteroaromatic ring with adjacent carbon atoms; and P represents an atomic group which includes an atom(s) selected from a hydrogen atom, a carbon atom, an oxygen atom, a sulfur atom, a silicon atom and a boron atom, and which is needed to form a ring structure group with adjacent two oxygen atoms and two carbon atoms;

  本发明提供了一种新型茜素衍生物化合物和一种简化且低成本的制备茜素衍生物化合物的方法，包括：使用式（3）表示的化合物获得式（2）表示的化合物；使用式（2）表示的化合物获得式（1）表示的茜素衍生物化合物；在式（1）至（3）中，R1表示氢原子或取代基；n表示1至3的整数，L表示特定的烷基基团；Q表示需要与相邻的碳原子形成芳香环或杂芳环的原子基团；P表示包括从氢原子、碳原子、氧原子、硫原子、硅原子和硼原子中选择的一个或多个原子的原子基团，需要与相邻的两个氧原子和两个碳原子形成环状结构基团。
• Pyridine and Pyrazine derivative for the Treatment of CF
  申请人：BAETTIG Urs

  公开号：US20150045364A1

  公开（公告）日：2015-02-12

  The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了吡啶和吡嗪衍生物，能够恢复或增强突变型和/或野生型CFTR的功能，以治疗囊性纤维化、原发性纤毛运动障碍、慢性支气管炎、慢性阻塞性肺疾病、哮喘、呼吸道感染、肺癌、口干症和角膜结膜炎，或便秘（IBS、IBD、阿片类药物引起的）。还包括含有这些衍生物的药物组合物。